Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic Announces FDA Approval Of SenSight Directional Lead System For Treating Movement Disorders

Executive Summary

Medtronic said it will launch the SenSight DBS in the US after winning FDA approval. The total DBS market is expected to exceed $1bn by 2024, according to Meddevicetracker.

You may also be interested in...



FDA Approves Medtronic’s Arctic Front For ‘First-Line’ Treatment For AFib

The new approval allows Medtronic to promote cryoablation as the first option for patients with recurrent symptomatic paroxysmal atrial fibrillation. Previously, it was only approved for patients who had already tried to manage their atrial fibrillation with drugs.

Medtronic Bounces Back During Quarter Four Of Financial Year 2021 As Procedure Volumes Normalize

Medtronic reported strong growth for the past quarter, with CEO Geoff Martha emphasizing the medtech giant’s efforts in M&A and R&D.

Women’s Health Expert Panel Addresses Challenges, Opportunities In Post-Roe Era

After years of underfunding, stigmatization and lack of research, companies working on products and services that address women’s health care are gaining traction. But the sector also faces unique challenges, such as gaining approval for ads on major social media platforms.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT144032

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel